Monica L Acevedo
Overview
Explore the profile of Monica L Acevedo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
168
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rivera-Perez D, Mendez C, Diethelm-Varela B, Melo-Gonzalez F, Vazquez Y, Meng X, et al.
Front Immunol
. 2024 May;
15:1372193.
PMID: 38812507
Background: Vaccine effectiveness against SARS-CoV-2 infection has been somewhat limited due to the widespread dissemination of the Omicron variant, its subvariants, and the immune response dynamics of the naturally infected...
2.
Gaete-Argel A, Saavedra-Alarcon V, Saure D, Alonso-Palomares L, Acevedo M, Alarcon M, et al.
Front Immunol
. 2023 Mar;
14:1135478.
PMID: 36999018
Introduction: Booster doses of SARS-CoV-2 vaccines improve seroconversion rates in solid organ transplant recipients (SOTRs) but the impact of homologous and heterologous booster doses in neutralizing antibody (NAb) titers and...
3.
Saure D, ORyan M, Torres J, Zuniga M, Soto-Rifo R, Valiente-Echeverria F, et al.
Lancet Microbe
. 2023 Jan;
4(3):e149-e158.
PMID: 36716754
Background: By June 30, 2022, 92·6% of the Chilean population older than 18 years had received a full primary SARS-CoV-2 vaccine series, mostly with CoronaVac (Sinovac Biotech), and 78·4% had...
4.
Acevedo M, Gaete-Argel A, Alonso-Palomares L, Montes de Oca M, Bustamante A, Gaggero A, et al.
Nat Microbiol
. 2023 Jan;
8(2):360.
PMID: 36658398
No abstract available.
5.
Acevedo J, Acevedo M, Gaete-Argel A, Araos R, Gonzalez C, Espinoza D, et al.
Clin Microbiol Infect
. 2022 Nov;
29(4):541.e1-541.e7.
PMID: 36436704
Objectives: To determine the impact of a booster dose on the humoral response in individuals inoculated with a complete schedule of any SARS-CoV-2 vaccine, we evaluated the neutralizing antibody (NAb)...
6.
Soto J, Melo-Gonzalez F, Gutierrez-Vera C, Schultz B, Berrios-Rojas R, Rivera-Perez D, et al.
mBio
. 2022 Nov;
13(6):e0131122.
PMID: 36383021
Multiple vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been evaluated in clinical trials. However, trials addressing the immune response in the pediatric population are scarce. The inactivated...
7.
Galvez N, Pacheco G, Schultz B, Melo-Gonzalez F, Soto J, Duarte L, et al.
Elife
. 2022 Oct;
11.
PMID: 36226829
Background: The development of vaccines to control the coronavirus disease 2019 (COVID-19) pandemic progression is a worldwide priority. CoronaVac is an inactivated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine...
8.
Schultz B, Melo-Gonzalez F, Duarte L, Galvez N, Pacheco G, Soto J, et al.
mBio
. 2022 Aug;
13(4):e0142322.
PMID: 35946814
CoronaVac is an inactivated SARS-CoV-2 vaccine approved by the World Health Organization (WHO). Previous studies reported increased levels of neutralizing antibodies and specific T cells 2 and 4 weeks after...
9.
Vargas L, Valdivieso N, Tempio F, Simon V, Sauma D, Valenzuela L, et al.
BMC Med
. 2022 Jun;
20(1):216.
PMID: 35676738
Background: Chile was severely affected by COVID19 outbreaks but was also one of the first countries to start a nationwide program to vaccinate against the disease. Furthermore, Chile became one...
10.
Acevedo M, Gaete-Argel A, Alonso-Palomares L, Montes de Oca M, Bustamante A, Gaggero A, et al.
Nat Microbiol
. 2022 May;
7(6):929.
PMID: 35606424
No abstract available.